Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
RIG2
vs
DAX Index
Over the past 12 months, RIG2 has significantly outperformed DAX Index, delivering a return of +44% compared to DAX Index's +7% growth.
Stocks Performance
RIG2 vs DAX Index
Performance Gap
RIG2 vs DAX Index
Create a free account · No card needed
Performance By Year
RIG2 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Richter Gedeon Vegyeszeti Gyar Nyrt
Glance View
Richter Gedeon is a pharmaceutical company that develops, manufactures, and sells prescription medicines, with a strong focus on treatments for women’s health, central nervous system disorders, and some generic drugs. It also makes active pharmaceutical ingredients and drug products that are used in its own medicines and sold to other drugmakers. Its main customers are hospitals, doctors, pharmacies, health systems, and partner pharma companies in many countries. The company makes money by selling branded medicines, generic products, and active ingredients, and by licensing or partnering on some of its drug programs. That mix gives it both direct sales and business-to-business revenue. Because drug development is slow and heavily regulated, Richter’s business depends on scientific research, manufacturing quality, and approval processes more than on retail-style selling. What makes Richter different is its role as both a medicine developer and a manufacturer of pharmaceutical ingredients. That means it is not just packaging products made elsewhere; it sits deeper in the drug supply chain and can profit from multiple steps, from research to production to sale. For investors, it is best thought of as a specialty drug company with a long-established presence in Central and Eastern Europe and a wider international reach.
Create a free account · No card needed